X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs GLENMARK PHARMA - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH GLENMARK PHARMA PANACEA BIOTECH/
GLENMARK PHARMA
 
P/E (TTM) x 80.4 13.6 589.7% View Chart
P/BV x 1.8 3.8 46.8% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 PANACEA BIOTECH   GLENMARK PHARMA
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
GLENMARK PHARMA
Mar-16
PANACEA BIOTECH/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1491,262 11.8%   
Low Rs82672 12.3%   
Sales per share (Unadj.) Rs84.1270.6 31.1%  
Earnings per share (Unadj.) Rs-18.324.9 -73.6%  
Cash flow per share (Unadj.) Rs-6.734.4 -19.5%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs83.7151.3 55.3%  
Shares outstanding (eoy) m61.25282.16 21.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.43.6 38.4%   
Avg P/E ratio x-6.338.9 -16.2%  
P/CF ratio (eoy) x-17.228.1 -61.4%  
Price / Book Value ratio x1.46.4 21.6%  
Dividend payout %08.0 0.0%   
Avg Mkt Cap Rs m7,074272,778 2.6%   
No. of employees `0002.810.0 27.4%   
Total wages/salary Rs m1,44913,782 10.5%   
Avg. sales/employee Rs Th1,874.17,614.9 24.6%   
Avg. wages/employee Rs Th527.01,374.8 38.3%   
Avg. net profit/employee Rs Th-407.7700.2 -58.2%   
INCOME DATA
Net Sales Rs m5,15476,340 6.8%  
Other income Rs m100356 28.0%   
Total revenues Rs m5,25476,696 6.8%   
Gross profit Rs m-76614,172 -5.4%  
Depreciation Rs m7112,691 26.4%   
Interest Rs m1,5031,789 84.0%   
Profit before tax Rs m-2,88110,048 -28.7%   
Minority Interest Rs m110-   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,7710-   
Tax Rs m173,028 0.6%   
Profit after tax Rs m-1,1217,019 -16.0%  
Gross profit margin %-14.918.6 -80.1%  
Effective tax rate %-0.630.1 -1.9%   
Net profit margin %-21.89.2 -236.6%  
BALANCE SHEET DATA
Current assets Rs m3,81059,096 6.4%   
Current liabilities Rs m8,36540,018 20.9%   
Net working cap to sales %-88.425.0 -353.7%  
Current ratio x0.51.5 30.8%  
Inventory Days Days15675 207.7%  
Debtors Days Days67119 56.4%  
Net fixed assets Rs m14,48039,075 37.1%   
Share capital Rs m61282 21.7%   
"Free" reserves Rs m90330,281 3.0%   
Net worth Rs m5,12742,703 12.0%   
Long term debt Rs m5,83224,873 23.4%   
Total assets Rs m19,433111,026 17.5%  
Interest coverage x-0.96.6 -13.9%   
Debt to equity ratio x1.10.6 195.3%  
Sales to assets ratio x0.30.7 38.6%   
Return on assets %2.07.9 24.8%  
Return on equity %-21.916.4 -133.0%  
Return on capital %3.617.5 20.8%  
Exports to sales %24.543.3 56.7%   
Imports to sales %10.27.4 137.0%   
Exports (fob) Rs m1,26433,044 3.8%   
Imports (cif) Rs m5255,672 9.3%   
Fx inflow Rs m1,53936,945 4.2%   
Fx outflow Rs m94261,066 1.5%   
Net fx Rs m597-24,122 -2.5%   
CASH FLOW
From Operations Rs m5993,449 17.4%  
From Investments Rs m-438-8,802 5.0%  
From Financial Activity Rs m-3036,986 -4.3%  
Net Cashflow Rs m-141934 -15.1%  

Share Holding

Indian Promoters % 74.5 48.3 154.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 6.9 8.7%  
FIIs % 1.3 34.4 3.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 10.5 224.8%  
Shareholders   10,259 56,727 18.1%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   IPCA LABS  NOVARTIS  ALEMBIC PHARMA  MERCK LTD  SANOFI INDIA  

Compare PANACEA BIOTECH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Recovery of Global Markets, Apex Frozen Food IPO & Cues to Watch Out Today(Pre-Open)

Indian stock markets remained range-bound in lacklustre trade on Tuesday as market participants kept to the sidelines in the absence of clear triggers.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Glenmark: High Costs hit the Bottom line (Quarterly Results Update - Detailed)

Nov 8, 2016

Glenmark has announced its 2QFY16 results. The company has reported 15.7% YoY growth in net sales and 3.5% YoY increase in net profits. Here is our analysis of the results.

Glenmark: Other Income Boosts Profit Growth (Quarterly Results Update - Detailed)

Sep 6, 2016

Glenmark has announced its 1QFY17 results. The company has reported 15.8% YoY growth in net sales and 24% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Aug 22, 2017 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 8-QTR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS